NCT03381651

Different Radiation Dose of Neoadjuvant Chemoradiation for Resectable Thoracic Esophageal Squamous Carcinoma

Different Radiation Dose of Neoadjuvant Chemoradiation Followed by Surgery in Treating Patients with Locally Advanced, Resectable Thoracic Esophageal Cancer

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 147 (actual)
• Sponsor: Zhejiang Cancer Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

Esophageal cancer is one of the most common cancers worldwide, while more than half new cases and deaths occurred in China. Surgery is the main curative treatment for this disease, the 5-year survival of EC remains poor, since most diseases are diagnosed at advanced stages. In last decades, several large clinical trials and meta-analyses have demonstrated that neo-adjuvant chemoradiotherapy followed by surgery can significantly increase the overall survival of patients with EC compared with surgery alone, while no effect of nCRT was apparent on postoperative health-related quality of life . However, the optimal radiation dose and surgery timing are still unknown. The investigators hypothesize that patients who receive higher dose (50.4Gy/28F) of neoadjuvant chemoradiation will have better pathologic response and progress-free survival compared to lower dose (41.4Gy/23F) of chemoradiation followed by surgery.

Conditions

• Esophageal Carcinoma
• Neoadjuvant Chemoradiotherapy
• Surgery

Interventions

Type	Name	Description
RADIATION	Higher dose (50.4Gy/28F) of neoadjuvant chemoradiation	50.4Gy/28F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly
RADIATION	Lower dose (41.4Gy/23F) of neoadjuvant chemoradiation	41.4Gy/23F radiation and concurrent chemotherapy with paclitaxel plus CBP used weekly

Timeline

• Start date: 2018-02-22
• Primary completion: 2021-02-22
• Completion: 2023-02-22
• First posted: 2017-12-22
• Last updated: 2024-11-18

Locations

2 sites across 1 country: China